Levetiracetam is more effective in the treatment of epilepsy.
Levetiracetam belongs to a new class of antiepileptic drugs that inhibit hippocampal epileptiform burst discharges and selectively inhibit supersynchronization of epileptiform burst discharges and seizure propagation. Double-blind, randomized, placebo-controlled studies have found that levetiracetam leads to a significant decrease in the number of seizures in patients with refractory epilepsy, and can be used as an additive for refractory focal seizures, tonic-paroxysmal seizures, and others.
Levetiracetam is used clinically as add-on therapy for partial-onset seizures in adults and children over 4 years of age with epilepsy. The most common adverse reactions are drowsiness, malaise, and dizziness, often occurring at the beginning of treatment. The most common adverse reactions in children are drowsiness, hostility, nervousness, moodiness, agitation, loss of appetite, malaise and headache.
Levetiracetam is contraindicated in patients who are hypersensitive to levetiracetam or who are allergic to pyrrolidone derivatives or any other ingredient.
Based on current clinical practice, if discontinuation of this product is required, it is recommended that it be stopped gradually. Levetiracetam should be used under the supervision of a physician and should not be taken on its own to avoid adverse effects.